COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #9 of 230
4/1 Early treatment study
Huang et al., Journal of Molecular Cell Biology, Volume 12, Issue 4, April 2020, 322–325, doi:10.1093/jmcb/mjaa014 (Peer Reviewed)
Treating COVID-19 with Chloroquine
Source   PDF   Share   Tweet
22 patients. All CQ patients discharged by day 14 versus 50% of Lopinavir/Rotinavir patients. Symptom onset to treatment 2.5 days for CQ vs. 6.5 days for Lopinavir/Rotinavir.

Huang et al., 4/1/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 18 authors, dosage chloroquine 500mg bid days 1-10.
risk of no recovery at day 14, 91.7% lower, RR 0.08, p = 0.02, treatment 0 of 10 (0.0%), control 6 of 12 (50.0%).
risk of no improvement in pneumonia at day 14, 83.0% lower, RR 0.17, p = 0.22.
Details of all 230 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit